TrialBreast cancer research and treatment2015

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.

Michael R Clemens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.